Key result
Spironolactone decreased atrial fibrillation inducibility and duration (P<0.05) and atrial fibrosis (P<0.01) in dogs with pacing-induced congestive heart failure.
Why the study?
Does spironolactone prevent atrial fibrillation and atrial fibrosis in a dog model of pacing-induced congestive heart failure?
RCT (n=21)
randomly divided
Does spironolactone prevent atrial fibrillation and atrial fibrosis in a dog model of pacing-induced congestive heart failure?
Spironolactone attenuates atrial electrical remodeling and fibrosis, reducing AF inducibility in a canine model of pacing-induced heart failure.
No takes yet. Share an insight, caveat, or question.
May reduce experimental AF in canine HF; leaves open clinical translation pending human trials.
Yang et al. (2008) conducted an RCT in congestive heart failure (n=21). spironolactone vs. sham-operated group and control group was evaluated on atrial electrical remodeling and fibrosis. Spironolactone decreased atrial fibrillation inducibility and duration (P<0.05) and atrial fibrosis (P<0.01) in dogs with pacing-induced congestive heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: